UNITE-PD: The Effect of Compensation Strategies on Gait Impairment in Parkinson's Disease

Sponsor
Radboud University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT06142448
Collaborator
KU Leuven (Other), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Other), IRCCS Policlinico San Martino, Genova, Italy (Other)
384
1
2
36.4
10.6

Study Details

Study Description

Brief Summary

Gait disturbances are disabling and common in Parkinson's disease (PD). Patients use many different, and typically self-developed, strategies to compensate for their walking abnormalities. There is a wide variety of compensatory strategies, of which external and internal cueing are the most commonly known. External cueing refers to externally produced predictive stimuli such as a metronome, whereas internal cueing refers to a movement reference generated internally, such as counting while walking. The efficacy of external and internal cueing varies dramatically across patients, and some patients can even be identified as 'non-responders' to a particular cue. Consequently, a one-size-fits-all approach simply does not suffice, which increases the need for better understanding of the key mechanisms behind these compensation strategies. Additionally, it is still unknown how the efficacy of compensation strategies changes longitudinally. The goal of this project is to address these questions. We aim to investigate whether the efficacy of internal and external cueing changes over time, and whether it is differentially affected in responders and non-responders. In order to work towards a more personalized treatment for patients with PD, we also aim to identify potential patient characteristics that can mediate the actual use of compensation strategies in daily life.

The multicenter UNITE-PD project is divided in a joint package and individual site-specific packages. All partners will investigate the neural working mechanisms of compensation strategies in PD from different angles in the site-specific packages. The joint package focusses on the long-term effect of the compensation strategies and the potential patient characteristics that can influence the efficacy of the compensation strategies. In this project we define responders and non-responders to external and/or internal cueing. With the use of extensive clinimetrics we aim to identify patient characteristics that might influence the efficacy. With the use of a custom made cueing app (which will be applied during a follow up period of six months), we investigate the long-term effect of cueing in the responders.

Together, all centers aim to include a total of 384 participants (Netherlands N = 104, Belgium N =90, Israel N = 75, Italy N = 115). Importantly, this sample size is not based on the joint workpackage described here, but on the numbers needed for the individual site-specific work packages.

Condition or Disease Intervention/Treatment Phase
  • Device: Cueing app
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
384 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Unravelling the Neural Mechanisms Underlying Compensation Strategies for Gait Impairments in Parkinson's Disease: a Transnational, Multimodal Approach
Anticipated Study Start Date :
Nov 20, 2023
Anticipated Primary Completion Date :
Dec 1, 2026
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Responders

Device: Cueing app
All participants that are included come to the movement lab for the baseline measurement. During this baseline measurement we perform extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period they will also use a mobile application that provides a rhythmic auditory stimulus and records the use of this application. After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which we repeat the baseline measurement to evaluate the effect of long-term cueing.

No Intervention: Non-responders

Outcome Measures

Primary Outcome Measures

  1. Gait Variability [Six months]

    Gait variability defined as the coefficient of variation of stride time. We will compare gait variability between the baseline condition, and the cueing conditions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women of age > 18 years with idiopathic Parkinson's disease;

  • Written informed consent.

Exclusion Criteria:
  • Daily usage of compensation strategies for the past month;

  • Presence of deep brain stimulation (DBS);

  • Presence of severe co-morbidity limiting ambulation (e.g. stroke, orthopaedic problems);

  • Inability to walk unaided (with the exception of a customary cane);

  • Inability to walk for > 3 minutes consecutively;

  • Severe auditory impairments, hampering perception of auditory cues;

  • Severe cognitive impairment (MMSE < 21)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radboudumc Nijmegen Netherlands

Sponsors and Collaborators

  • Radboud University Medical Center
  • KU Leuven
  • Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  • IRCCS Policlinico San Martino, Genova, Italy

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT06142448
Other Study ID Numbers:
  • 113692
First Posted:
Nov 21, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Radboud University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2023